【摘要】 近年来，非小细胞肺癌（non-small cell lung cancer, NSCLC）静脉化疗逐渐进入平台期，缓解率 （response rate, RR）、平均总生存期（overall survival, OS）无明显改善；随着分子生物学发展，以表皮生长因子受 体（epidermal growth factor receptor, EGFR）为靶点的EGFR酪氨酸激酶抑制剂（EGFR-tyrosine kinase inhibitors, EGFR- After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.
effect on the NSCLC. But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents. This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs.
After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment. Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.
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